Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Multiple Myeloma Market to Exhibit a Remarkable Growth of USD 38.94 Billion by 2029, Size, Share, Trends, Key Drivers, Growth and Opportunity Analysis
March 22, 2023 13:30 ET
|
Data Bridge Market Research
HOUSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Data Bridge Market Research completed a qualitative study titled "Multiple Myeloma Market" with 100+ market data tables, pie charts, graphs, and figures...
Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myeloma
March 16, 2023 03:00 ET
|
Anaveon
BASEL, Switzerland, March 16, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the first patient dosed with ANV419 in the OMNIA-2 (ANV419-102) study - a...
International Myeloma Foundation (IMF) Launches #MYelomaSTORY Campaign for Myeloma Action Month in March 2023
February 23, 2023 08:45 ET
|
International Myeloma Foundation
STUDIO CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- With the International Myeloma Foundation (IMF) at the forefront, Myeloma Action Month is held every year for the whole month of March to...
International Myeloma Foundation (IMF) Returns to In-Person Patient and Family Seminars in 2023, Announces Boca Raton Event
February 02, 2023 08:45 ET
|
International Myeloma Foundation
BOCA RATON, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced that this year’s first Patient and Family Seminar is taking place in-person and...
Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
December 11, 2022 10:00 ET
|
Harpoon Therapeutics
Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with relapsed/refractory multiple myeloma77% (10/13) objective response rate (ORR) observed...
CURE Media Group announces D.L. Hughley as keynote panel moderator for the 2022 Multiple Myeloma Heroes and Health Equity Heroes awards
December 05, 2022 13:38 ET
|
CURE Media Group
CRANBURY, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than 1 million patients,...
International Myeloma Foundation Named Winner of 2022 Amazon Web Services IMAGINE Grant for Nonprofits
December 01, 2022 08:45 ET
|
International Myeloma Foundation
STUDIO CITY, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced it has been selected as a winner of the 2022 Amazon Web Services (AWS) IMAGINE...
CURE Media Group announces 2022 Multiple Myeloma Heroes®
November 17, 2022 09:00 ET
|
CURE Media Group
CRANBURY, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than 1 million patients,...
Scip & Savor for a Cure Fundraiser Benefits the International Myeloma Foundation (IMF) and Family Reach
October 27, 2022 08:45 ET
|
International Myeloma Foundation
STUDIO CITY, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced the details of the recent fundraising celebration hosted by Fatima Scipione and her...
The Annual Miracles for Myeloma 5K Hybrid Run/Walk Celebrates 10th Anniversary
September 29, 2022 08:45 ET
|
International Myeloma Foundation
CLARK, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- The Annual Miracles for Myeloma 5K Hybrid Run/Walk will be celebrating its tenth anniversary this year. For the past nine years, this annual event has...